Sigilon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.sigilon.com
Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy
Phase 1
Withdrawn
- Conditions
- MPS1-SMPS IMPS1-HS
- Interventions
- Combination Product: SIG-005 (hIDUA Producing Spheres)
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sigilon Therapeutics, Inc.
- Registration Number
- NCT05665036
- Locations
- 🇬🇧
Clinical Study Site, Salford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath